跳至主要内容
临床试验/NCT04080882
NCT04080882已完成2 期

A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Platysmal Bands

Galderma R&D8 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2019年9月25日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
Galderma R&D
入组人数
80
试验地点
8
主要终点
Responder Rate at Month 1 for a Single Dose of abobotulinumtoxinA Compared to Placebo

研究概览

简要总结

Interventional phase 2 study to evaluate safety and efficacy of abobotulinumtoxinA for the treatment of platysmal bands.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Moderate to severe platysmal bands at maximum contraction as assessed by the Investigator using a photographic scale
  • Platysmal bands graded as Level 3 or 4 at maximum contraction as assessed by the subject using a photographic scale

排除标准

  • Botulinum toxin treatment of any serotype below the lower orbital rim, in the neck or chest within 12 months prior to study treatment

结局指标

主要结局

Responder Rate at Month 1 for a Single Dose of abobotulinumtoxinA Compared to Placebo

时间窗: Month 1 after treatment

A responder is defined as a subject who achieves grade 1 or 2 in platysmal band severity on the Investigator Live Assessment (ILA).

次要结局

未报告次要终点

研究者

发起方
Galderma R&D
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验